Search Results - "Bianchini, D"

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) by Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J.S., Massard, C.

“…Androgen receptor (AR) signalling remains critically important in metastatic castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III…”
Get full text

Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study by Marzano, A.V., Genovese, G., Casazza, G., Moltrasio, C., Dapavo, P., Micali, G., Sirna, R., Gisondi, P., Patrizi, A., Dini, V., Bianchini, D., Bianchi, L., Fania, L., Prignano, F., Offidani, A., Atzori, L., Bettoli, V., Cannavò, S.P., Venturini, M., Bongiorno, M. R., Costanzo, A., Fabbrocini, G., Peris, K.

“…Summary Background The anti‐tumour necrosis factor (TNF)‐α adalimumab is the only licenced biologic for moderate‐to‐severe hidradenitis suppurativa (HS). No…”
Get full text

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use by Lorente, D., Mateo, J., Templeton, A.J., Zafeiriou, Z., Bianchini, D., Ferraldeschi, R., Bahl, A., Shen, L., Su, Z., Sartor, O., de Bono, J.S.

“…We investigated the value of the neutrophil–lymphocyte ratio (NLR) in patients with CRPC treated with chemotherapy in the phase III TROPIC trial. High NLR was…”
Get full text

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone by Bianchini, D, Lorente, D, Rodriguez-Vida, A, Omlin, A, Pezaro, C, Ferraldeschi, R, Zivi, A, Attard, G, Chowdhury, S, de Bono, J.S

“…Abstract Background The new generation anti-androgen enzalutamide and the potent CYP17 inhibitor abiraterone have both demonstrated survival benefits in…”
Get full text

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts by Lorente, D., Olmos, D., Mateo, J., Dolling, D., Bianchini, D., Seed, G., Flohr, P., Crespo, M., Figueiredo, I., Miranda, S., Scher, H.I., Terstappen, L.W.M.M., de Bono, J.S.

“…The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating…”
Get full text

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer by Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., de Bono, J.S.

“…Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic…”
Get full text

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? by Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., Maier, G., Reid, A.H.M., Mulick Cassidy, A., Olmos, D., Attard, G., de Bono, J.

“…Abiraterone and docetaxel are both approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone pre-docetaxel is…”
Get full text

Modifiable and non-modifiable risk factors affecting walking recovery after hip fracture by Pioli, G., Lauretani, F., Pellicciotti, F., Pignedoli, P., Bendini, C., Davoli, M. L., Martini, E., Zagatti, A., Giordano, A., Nardelli, A., Zurlo, A., Bianchini, D., Sabetta, E., Ferrari, A., Tedeschi, C., Lunardelli, M. L.

“…Summary Modifiable and non-modifiable predictors of mobility recovery were analyzed on a sample of 774 hip fracture patients according to pre-fracture…”
Get full text

Visceral Disease in Castration-resistant Prostate Cancer by Pezaro, Carmel J, Omlin, Aurelius, Lorente, David, Nava Rodrigues, Daniel, Ferraldeschi, Roberta, Bianchini, Diletta, Mukherji, Deborah, Riisnaes, Ruth, Altavilla, Amelia, Crespo, Mateus, Tunariu, Nina, de Bono, Johann S, Attard, Gerhardt

“…Abstract Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359…”
Get full text

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents by Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G

“…Background: Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer…”
Get full text

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer by Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C

“…Background: Prostate cancer remains dependent of androgen receptor (AR) signalling, even after emergence of castration resistance. EZN-4176 is a…”
Get full text

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone by Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C.J., Petrylak, D.P., Attard, G., Shen, L., Fizazi, K., de Bono, J.

“…Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II…”
Get full text

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI by Messiou, C., Collins, D. J., Giles, S., de Bono, J. S., Bianchini, D., de Souza, N. M.

“…Objectives To determine whether changes in ADC of bone metastases secondary to prostate carcinoma are significantly different in responders compared with…”
Get full text

Stroke or Stramonium? A novel stroke mimic by Colella, M., Strada, L., Bianchini, D., Ajmar, G., Del Sette, M.

Get full text

Cerebral vasoreactivity and intima-media thickness in Down syndrome: A case-control study by Colella, M., Stilo, C., Cocchella, A., Bianchini, D., Pilotto, A., Del Sette, P., Musolino, R.

“…Subjects with Down Syndrome (DS) have high prevalence of cerebral vascular amyloidosis, cognitive decline and dementia. In Alzheimer Disease, impaired…”
Get full text

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer by Pezaro, C, Mukherji, D, Tunariu, N, Cassidy, A M, Omlin, A, Bianchini, D, Seed, G, Reid, A H M, Olmos, D, de Bono, J S, Attard, G

“…Background: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression…”
Get full text

Air contamination measurements for the evaluation of internal dose to workers in nuclear medicine departments by De Massimi, B., Bianchini, D., Sarnelli, A., D’Errico, V., Marcocci, F., Mezzenga, E., Mostacci, D.

“…Radionuclides handled in nuclear medicine departments are often characterized by high volatility and short half-life. It is generally difficult to monitor…”
Get full text

PI3K/AKT pathway deleterious mutations in lethal prostate cancer by Rescigno, P., Rediti, M., Dolling, D., Rodrigues, D.N., Bianchini, D., Riisnaes, R., Messina, C., Barrero, M., Petremolo, A., Sharp, A., Sumanasuriya, S., Seed, G., Figueiredo, I., Miranda, S., Goodall, J., Mateo, J., Chandler, R., Yuan, W., Carreira, S., de Bono, J.S.

Get full text

Ocular motility alterations in orbital fractures: pre-post evaluation in maxillofacial surgical treatment by Arrico, L, Migliorini, R, Bianchini, D, Salducci, M, Collini, S, Malagola, R

“…The study aims to investigate the ability of maxillofacial surgery to reduce strabismus and improve ocular clinical symptomatology in patients with fracture of…”
Get full text

Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status by Jayaram, A., Nowakowska, K., Mateo, J., Hernandez, T., Kumar, S., Fulton, B., Nava Rodrigues, D., Riisnaes, R., Zukiwski, A., Proniuk, S., Bexon, A.S., Bisaha, J., Bianchini, D., Zafeiriou, Z., Lopez, R.P., Tunariu, N., Pacey, S., Jones, R., de Bono, J. Sebastian, Attard, G.

Get full text